Why Sequencing Isn’t the Bottleneck Anymore

Sequencing is becoming a commodity, while clinical interpretation, data governance, and workflow integration are now the limiting factors. The cost curve is no longer the story – by 2024, a complete human genome is cited at roughly ~USD 500 in the genetics community materials.

As a result, the new differentiator is whether organizations are able to convert genomes into decisions without creating privacy, liability, and reimbursement drag.

Commercially, market researchers now model genomics as a high-growth platform market, expanding at a 19.8% CAGR from USD 50.1B (2025) to USD 304.8B (2035). But the operational reality is that value follows where clinical-grade evidence, lab QA, and scalable analytics converge.

Where Genomics Is Scaling: Patents, Hiring, and Hub Concentration

In May 2025, WHO member states adopted the first rare diseases resolution, noting that over 300 million people globally live with more than 7000 rare diseases, most beginning in childhood. This effectively positions faster diagnosis and access as a global health priority.

In England, genomics is shifting from innovation programs to system capacity. For example, the UK government’s 10-Year Health Plan states the NHS Genomic Medicine Service delivers over 850 000 genomic tests annually via 7 Genomic Laboratory Hubs. It forecasts that half of healthcare interactions will be informed by genomic insights by 2035.

The genomics sector advances as innovations in sequencing technologies, computational biology, and precision medicine reshape global healthcare and research ecosystems. Our database records 1235+ startups within a broader pool of 13 630+ companies active in the genomics landscape.

Supporting this ecosystem is a global workforce of 1.2 million professionals, with 480+ new employees added in the last year.

On the city level, London, Cambridge, New York City, San Francisco, and San Diego emerge as major centers where research institutions, startups, and biotech companies converge.

The industry is expected to increase from USD 50.1 billion in 2025 to USD 304.8 billion by 2035, with a compound annual growth rate (CAGR) of 19.8% from 2025 to 2035.

 

 

The market was divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Among these, North America led the global genomics market in 2024, holding the largest share at 42.65%.

Within sequencing, whole-genome sequencing is scaling faster than many clinical pathways. Grand View Research estimates that the global whole genome sequencing market is expected to reach USD 6.67 billion by 2030.

 

 

Applied Genomics in Practice: Five Vendors Targeting Workflow

Ellis Bio offers Epigenomic Kits

US-based startup Ellis Bio develops SuperMethyl Fast and SuperMethyl Max, two bisulfite conversion kits that strengthen DNA methylation analysis across research and clinical workflows.

SuperMethyl Fast performs C-to-U conversion through an optimized rapid-reaction chemistry by using ready-to-apply reagents that minimize handling and maintain conversion efficiency.

It supports a broad input range, preserves high DNA recovery, and integrates into downstream applications such as polymerase chain reaction (PCR), microarrays, and next-generation sequencing.

In contrast, SuperMethyl Max uses ultra-mild bisulfite chemistry to preserve DNA integrity during conversion and enables accurate methylation profiling from inputs as low as 100 pg.

It achieves high C-to-T conversion, maintains longer fragment lengths, and ensures uniform guanine-cytosine (GC) coverage across promoter and GC-rich regions.

Lucid Genomics builds AI-powered Genome Analysis Software

German startup Lucid Genomics develops an AI-driven platform that unifies detection, prioritization, and interpretation of genetic variants across individual, family, and cohort analyses.

It processes complete genomic data by examining both coding and non-coding regions, extracting information from every base of the DNA sequence, and scoring mutations according to their potential pathogenicity.

Lucid Genomics deploys specialized AI models for variant detection and prioritization to reduce structural-variant false positives. Moreover, it achieves higher accuracy in ranking pathogenic mutations through its disease-agnostic scoring system and regulatory-aware expert layer.

Further, the platform evaluates genes across different samples in less time, while filtering noisy short-read datasets to reduce false positives.

Also, it detects the full spectrum of variants, including single-nucleotide variants (SNVs), insertions and deletions (InDels), structural variants, and repeat expansions.

It deepens interpretation through multi-omics integration by combining epigenetic signals, gene expression data, and 3D genome architecture to highlight biologically relevant mutations and presents results through integrated visualizations that simplify hypothesis generation.

Genorare makes a Rare Disease Diagnosis Platform

Dutch startup Genorare develops a privacy-preserving diagnostic platform that identifies rare diseases by combining encrypted data processing with advanced clinical reasoning models.

It begins by gathering genomic sequences, electronic health records (EHR) information, and laboratory results directly from the patient’s clinical environment. With this, it encrypts each dataset at the source through a unique public-private key pair so that no unprotected information leaves the originating system.

The platform then performs computation on this encrypted content using homomorphic techniques that allow pattern detection, phenotype mapping, and literature-driven inference without exposing the underlying records.

During this stage, structured phenotype ontologies and language-based analysis extract clinical meaning from medical notes to reveal candidate disorders while maintaining strict confidentiality.

Once processing concludes, the encrypted results are returned to the clinician, who decrypts them locally with the patient’s private key to view prioritized risk scores and actionable insights that support more precise decision-making.

OutSee offers a Phenotype Prediction AI Engine

UK-based startup OutSee develops Nomaly, a predictive genomics engine that interprets a single genome by modeling the biological mechanisms that drive disease rather than relying on association-based signals.

Nomaly analyzes variation across coding and non-coding regions to infer functional effects, while capturing multi-variant influences and cooperative interactions that shape complex traits. This supports consistent performance across small and large cohorts.

Also, it groups patients according to mechanistic similarity to reveal patterns that remain hidden when methods depend on known variants or established correlations.

Adalid Sciences provides a Lipid Nanoparticle Delivery System

Czech Republic-based startup Adalid Sciences develops structurally novel lipid nanoparticles to deliver nucleic acid therapeutics.

The startup synthesizes ionizable lipidoids with an adamantane-based architecture and evaluates their performance through detailed biophysical characterization and in vivo studies.

Moreover, it assists in protein replacement, monoclonal antibody expression, vaccines, RNA interference, and gene editing.

Three Growth Engines: NGS Scale, Functional Depth, Computational Acceleration

Innovation activity remains a core engine of growth. More than 48.9K applicants have filed for more than 192.6K patents, filed by 48,900 applicants. Further, a 2.30% yearly patent growth rate indicates sustained advancement to support the long-term evolution of tools and technologies that underpin precision medicine.

Discover the emerging trends in the genomics market along with their firmographic details:

Next-Generation Sequencing (NGS)

This segment remains one of the largest and most established trends within the genomics sector. With 1565+ companies and 141.6K employees, including 80+ new hires in the past year, NGS drives high-throughput genomic analysis across research, diagnostics, and clinical applications.

Its 4.64% annual trend growth rate reflects steady expansion as sequencing becomes integral to disease detection, treatment planning, ancestry insights, and population-scale genomic programs.

Functional Genomics

It gains traction as researchers and biotech companies deepen their exploration of gene function, regulatory networks, and disease mechanisms. This domain includes 230+ companies employing 27.1K people, with 10+ new employees added in the last year.

An annual growth rate of 6.43% highlights rising investment in clustered regularly interspaced short palindromic repeats (CRISPR)-based screens, single-cell technologies, pathway mapping, and high-throughput assay platforms.

Computational Genomics

This represents one of the fastest-growing areas in the sector, driven by the expanding scale of genomic datasets and the need for advanced analytics. With 72 companies and 1800 employees, including 1 new hire in the past year, the segment demonstrates an annual growth rate of 12.68%.

This growth is increased by innovations in algorithm development, machine learning, cloud-based genomic processing, and integrated multi-omics analysis.

Capital Formation in Genomics: USD 49.1M Average Rounds & 11 530+ Active Investors

Strategic M&A is consolidating adjacent omics capabilities into genomics workflows. For instance, Thermo Fisher announced the completion of its Olink acquisition in July 2024, valuing Olink at USD 3.1 billion. This is a signal that scale players are buying differentiated assay platforms that can feed NGS readouts and accelerate multi-omics productization.

The average investment value of USD 49.1 million per round reflects strong confidence in both foundational research platforms and commercially advancing therapeutic and diagnostic technologies.

This momentum is supported by a broad network of over 11 530 investors. It includes venture capital firms, corporate biotech funds, pharmaceutical companies, and institutional investors specializing in life sciences. These investors have funded more than 3330 companies.

 

The top investors in the genomics sector have invested more than USD 23 billion.

 

Research Method and Data

This genomics outlook is built on the AI-powered StartUs Insights Discovery Platform, which continuously maps 9M+ global companies, 25K+ technologies and trends, and 190M patents, news articles, and market reports to connect R&D signals with real-world commercialization patterns. The scope prioritizes next-generation sequencing workflows, functional and computational genomics, multi-omics analytics, clinical variant interpretation, privacy-preserving genomic computation, and delivery/enabling technologies.

Using a five-year signal window, we track how the genomics stack is scaling through measurable adoption proxies – company formation and firmographics, patenting intensity, funding velocity, hiring activity, publication/news momentum, and global search behavior. This way, we identify where capability is consolidating, where competition is saturating, and which subtrends are transitioning from tool-building to deployment in clinical and population-health settings.